Tactiva Expands Next-Generation Cancer Immunotherapy Concepts

Tactiva is a new spinoff company of Roswell Park Cancer Institute in Buffalo, NY. Using a new and unique approach to adoptive cell transfer, Tactiva may be effective in treating diseases such as lung cancer and melanoma. Dr. Kunle Odunsi, Chief Medical Officer at Tactiva, explains the concept behind the two main types of T lymphocytes and how Tactiva turns "helper" cells into "killer" cells.